SCHEMBL6282910

SCHEMBL6282910

CC1(c2ccccc2)C(=O)N(C(=O)c2cccc3ccccc23)C(=O)N1CC(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.41
CBX7 O95931 2/20 0.39
CDY1; CDY1B Q9Y6F8 2/20 0.39
PTGDR Q13258 2/20 0.39
PTGDR2 Q9Y5Y4 2/20 0.39
CYP2C9 P11712 1/20 0.39
PTGER2 P43116 1/20 0.39
TACR1 P25103 1/20 0.38
KMT2A Q03164 2/20 0.38
AVPR1A P37288 1/20 0.38
NR4A1 P22736 1/20 0.38
NR4A2 P43354 1/20 0.38
NR4A3 Q92570 1/20 0.38
CDYL Q9Y232 2/20 0.38
FNTA P49354 1/20 0.37
FNTB P49356 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6285241 0.90 CBX7 (0.40) BCHECBX7CDY1; CDY1BCYP2C9TACR1
SCHEMBL6278686 0.87 BCHE (0.43) BCHECBX7CDY1; CDY1BPTGDRPTGDR2
SCHEMBL6278606 0.86 BCHE (0.42) BCHECBX7CDY1; CDY1BPTGDRPTGDR2
SCHEMBL6285454 0.83 CNR2 (0.45) TACR1KMT2AAVPR1AFNTAFNTB
SCHEMBL6285219 0.81 FNTA (0.50) TACR1KMT2AAVPR1AFNTAFNTB
SCHEMBL6287289 0.80 BCHE (0.41) BCHECBX7CDY1; CDY1BTACR1AVPR1A
SCHEMBL6282913 0.80 KMT2A (0.46) BCHECBX7CDY1; CDY1BKMT2ACDYL
SCHEMBL6287758 0.76 BCHE (0.40) BCHECBX7CDY1; CDY1BTACR1AVPR1A
SCHEMBL6282932 0.76 CDYL (0.42) BCHECBX7CDY1; CDY1BTACR1KMT2A
SCHEMBL6283110 0.76 AVPR1A (0.44) BCHECBX7CDY1; CDY1BTACR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919365-B2 Imidazolidinedione derivatives and use thereof as drugs SENJU PHARMACEUTICAL CO., LTD. (JP) 2005-07-19 US disclosed
US-20040110811-A1 Novel imidazolidinedione derivatives and use thereof as drugs SENJU PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed
EP-1384715-A1 NOVEL IMIDAZOLIDINEDIONE DERIVATIVES AND USE THEREOF AS DRUGS Senju Pharmaceutical Co., Ltd. (JP) 2004-01-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110811-A1 Novel imidazolidinedione derivatives and use thereof as drugs CMA1, TPSD1, TPSB2 BCHE 515/4885CBX7 2579/4885CDY1; CDY1B 2124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.